THE 2 MAJOR clinical trials pertaining to carotid endarterectomy (CE) that were conducted in North America and published in the past decade were landmark clinical achievements. These studies, the North American Symptomatic Carotid Endarterectomy Trial (NASCET)1,2 and the Asymptomatic Carotid Atherosclerosis Study (ACAS),3 brought hard data to a surgical procedure that had been performed for decades but without clear efficacy. The NASCET study found that patients with recently symptomatic 70% to 99% angiographic stenosis had robust benefit from CE, with a 17% absolute difference at 2 years in terms of recurrent ipsilateral stroke compared with medical management.
Chaturvedi S. Should the Multicenter Carotid Endarterectomy Trials Be Repeated?. Arch Neurol. 2003;60(5):774-775. doi:10.1001/archneur.60.5.774